Quinn Opportunity Partners LLC Acquires Shares of 20,000 Janux Therapeutics, Inc. (NASDAQ:JANX)

Quinn Opportunity Partners LLC acquired a new stake in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 20,000 shares of the company's stock, valued at approximately $1,071,000.

Several other hedge funds also recently bought and sold shares of JANX. FMR LLC boosted its stake in shares of Janux Therapeutics by 10.8% during the fourth quarter. FMR LLC now owns 8,669,941 shares of the company's stock valued at $464,189,000 after purchasing an additional 845,266 shares during the period. Wellington Management Group LLP boosted its position in Janux Therapeutics by 3,592.9% in the 4th quarter. Wellington Management Group LLP now owns 535,396 shares of the company's stock valued at $28,665,000 after buying an additional 520,898 shares during the period. Franklin Resources Inc. grew its stake in Janux Therapeutics by 2,519.6% in the 4th quarter. Franklin Resources Inc. now owns 497,287 shares of the company's stock worth $26,625,000 after acquiring an additional 478,304 shares in the last quarter. Pictet Asset Management Holding SA purchased a new position in shares of Janux Therapeutics during the fourth quarter worth approximately $20,602,000. Finally, Vanguard Group Inc. raised its stake in shares of Janux Therapeutics by 15.6% during the fourth quarter. Vanguard Group Inc. now owns 2,136,332 shares of the company's stock valued at $114,379,000 after acquiring an additional 288,402 shares in the last quarter. Institutional investors own 75.39% of the company's stock.

Janux Therapeutics Price Performance

Janux Therapeutics stock traded up $0.11 during midday trading on Tuesday, reaching $29.06. The company's stock had a trading volume of 552,625 shares, compared to its average volume of 853,740. Janux Therapeutics, Inc. has a 52-week low of $22.52 and a 52-week high of $71.71. The stock has a market capitalization of $1.72 billion, a P/E ratio of -24.84 and a beta of 3.27. The stock's 50-day simple moving average is $31.41 and its 200-day simple moving average is $44.02.

Remove Ads

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last released its earnings results on Thursday, February 27th. The company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.49) by $0.13. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. As a group, equities research analysts expect that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current fiscal year.

Insider Activity at Janux Therapeutics

In other Janux Therapeutics news, insider Andrew Hollman Meyer sold 3,334 shares of Janux Therapeutics stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $42.29, for a total transaction of $140,994.86. Following the completion of the sale, the insider now directly owns 82,139 shares in the company, valued at approximately $3,473,658.31. The trade was a 3.90 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Ra Capital Management, L.P. acquired 110,206 shares of the company's stock in a transaction dated Friday, March 7th. The stock was acquired at an average cost of $31.02 per share, for a total transaction of $3,418,590.12. Following the completion of the acquisition, the director now directly owns 10,141,287 shares in the company, valued at approximately $314,582,722.74. The trade was a 1.10 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 29.40% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on JANX shares. Lifesci Capital raised Janux Therapeutics to a "strong-buy" rating in a research note on Friday, December 27th. HC Wainwright restated a "buy" rating and issued a $70.00 price target on shares of Janux Therapeutics in a report on Monday, March 3rd. Wedbush reiterated an "outperform" rating and set a $76.00 price objective (up from $75.00) on shares of Janux Therapeutics in a research note on Friday, February 28th. Scotiabank reduced their price objective on shares of Janux Therapeutics from $62.00 to $41.00 and set a "sector perform" rating for the company in a research note on Friday, February 28th. Finally, William Blair reaffirmed an "outperform" rating on shares of Janux Therapeutics in a research report on Friday, January 10th. One research analyst has rated the stock with a hold rating, nine have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, Janux Therapeutics currently has a consensus rating of "Buy" and a consensus price target of $92.44.

Janux Therapeutics Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.